Health News

Gibson Oncology Expands Its Board of Directors With Accomplished Leadership in Oncology Clinical Development and Corporate Strategy

Editor

Health - Purple Foxy Ladies originally published at Health - Purple Foxy Ladies

Gibson Oncology Expands Its Board of Directors With Accomplished Leadership in Oncology Clinical Development and Corporate Strategy

MIAMI, March 14, 2023 (Newswire.com) - Gibson Oncology, a privately held Oncology preclinical and clinical development company advancing novel, targeted small molecule compounds that inhibit topoisomerase I and bind the G4 quadruplex in the cMyc promoter to inhibit cMyc expression as potent anticancer agents, welcomes two well-accomplished and experienced individuals within the life sciences industry, Dr. Fred Mermelstein and Dr. Mark Baganz. 

"We are delighted to have Dr. Fred Mermelstein and Dr. Mark Baganz join Gibson's Board of Directors. We look forward to their valuable contributions as Gibson further develops its oncology portfolio that uniquely attacks cancer through a dual mechanism: inhibition of TOPO 1 protein and reduction of cMyc expression levels through selective binding to G4 quadruplexes formed in the cMyc promoter region," stated Randall B. Riggs, President and CEO.  

Dr. Baganz is a corporate leader, entrepreneur, and board-certified diagnostic radiologist. He is the Founder and President of Chesapeake Medical Imaging, a subspeciality patient-centric diagnostic radiology practice with 12 locations in Maryland employing over 150 people. He was co-Founder and is a current Advisory Board member of SecureRAD-Purview, a medical IT and telehealth company and the sponsor of the Horos Project, an open-source medical image viewing platform with over 100,000 users on all continents and in over 170 countries. 

Fred Mermelstein, Ph.D., currently serves as President and CEO of Dynamic Cell Therapies since its founding in 2020 and Chairman of the board of Courage Therapeutics since its founding in 2019.  Between 2003 - 2010, Dr. Mermelstein founded Javelin Pharmaceuticals, Inc. (JAV), until its sale to Hospira, Inc., now Pfizer. He served as the CEO and President of Javelin, which developed Dyloject, an injectable anti-inflammatory for the treatment of post-operative pain. He founded PolaRx Biopharmaceuticals, Inc., in 1997, where he also served as Chief Scientific Officer until 1999, and on the team responsible for bringing Trisenox (Arsenic Trioxide for the treatment of Acute Promyelocytic Leukemia) to NDA completion, now marketed and sold worldwide by Teva. He also served on the board of NX Development Corp., between 2011 - 2018 which brought Gliolan to the market in the United States prior to its acquisition by SBI Pharma, Inc. Between 2008 and 2018, Dr. Mermelstein was a co-founder and served as Chairman of the Board of Pear Tree Pharmaceuticals, until its sale to Dare Biosciences, Inc. Dr. Mermelstein serves on several boards, including Harvard Institute of RNA Medicine, Rogosin Institute and Cornell-Weill Medical Center.

About Gibson Oncology:

Gibson Oncology is developing a novel class of proprietary drug candidates currently in clinical trials for the treatment of difficult-to-treat tumors. Our product candidates are first-in-class based upon dual activity at cMyc and TOPO-1 which will improve safety and efficacy and offer future approaches for treating several cancers. There are currently five (5) ongoing clinical studies funded by the National Institute of Health in patients with solid tumors and lymphomas. Additionally, Gibson has developed proprietary second-generation product candidates expanding modes of delivery and treatment approaches in both pediatric and adult populations. For more information, please visit www.gibsononcology.com.

Contact Information:
Randall B. Riggs
President & CEO
rriggs@gibsononcology.com
(502) 345-8911


Original Source: Gibson Oncology Expands Its Board of Directors With Accomplished Leadership in Oncology Clinical Development and Corporate Strategy

Health - Purple Foxy Ladies originally published at Health - Purple Foxy Ladies

More Stories

DocVA Launches Cutting-Edge Virtual Medical Assistant Services, Revolutionizing Healthcare Operations

DocVA Launches Cutting-Edge Virtual Medical Assistant Services, Revolutionizing Healthcare OperationsBoost Efficiency and Elevate Patient Care With DocVA’s New Virtual Assistant Services


FORT LAUDERDALE, Fla., July 18, 2024 (Newswire.com)
–
DocVA, a leader in the virtual medical assistant staffing industry with years of experience, announces the launch of its comprehensive suite of remote healthcare support services. This innovative offering aims to transform medical practices by providing highly skilled virtual assistants capable of handling various administrative and clinical support tasks.

Virtual Medical Assistant Provider Offers Tailored Solutions to Enhance Patient Care and Streamline Practice Operations

“The world of healthcare is constantly changing, and at DocVA, we’re committed to staying ahead of the curve,” said Nathaniel Barz, CEO of DocVA, who has a decade of experience delivering excellent customer service in the staffing industry. “Our mission is to help as many healthcare practices as possible in the U.S., Canada, and eventually the world by addressing the critical issues that arose post-COVID, such as staff burnout and shortages.”

Comprehensive Virtual Medical Assistant Services

DocVA’s range of services includes:

  • Virtual Medical Receptionist: Handling phone calls, scheduling appointments, managing prescription refill requests, and verifying insurance eligibility
  • Virtual Medical Billing and Insurance Assistant: Managing payments, insurance verification, claims submissions, and pre-authorizations
  • Virtual Medical Assistant: Updating medical records, coordinating with other providers, and fielding patient questions
  • Virtual Medical Scribe: Providing real-time documentation during patient exams, ensuring EMRs stay current

Benefits for All Stakeholders

By partnering with DocVA, healthcare providers can expect:

  • Improved office efficiency and smoother daily operations
  • Enhanced patient satisfaction through elite-level customer service
  • Significant cost savings compared to hiring in-house staff
  • HIPAA-compliant services that ensure patient privacy and data security
  • Flexibility to scale support based on practice needs
  • Reduced staff burnout and improved work-life balance
  • Increased profitability for practices

“Our virtual assistants create a win-win-win situation,” Nathan added. “Staff love it, doctors love it, and patients love it. We’re not just improving healthcare operations but also providing opportunities for people in developing countries to achieve an upper-middle-class lifestyle.”

About DocVA

DocVA is a seasoned virtual medical assistant staffing leader, with two years of specialized experience in the healthcare industry. Our team has placed thousands of virtual medical assistants in different practices across the U.S. Building on lessons learned from previous ventures, DocVA is dedicated to constant improvement and innovation. By leveraging cutting-edge AI technology and a team of highly skilled professionals, DocVA enables medical practices to streamline operations, improve patient care, and reduce operational costs.

Discover more about how DocVA is revolutionizing healthcare support at https://docva.com or contact:

Contact Information:

Nathaniel Barz 

Founder & CEO 

DocVA

clientmanager@docva.com
+1 (954) 304-9702
110 E. Broward Blvd., Suite 1700, Fort Lauderdale, Florida 33312, United States

Contact Information:

Nathaniel Barz

CEO

nbarz@docva.com

+1 (954) 304-9702

Original Source:

DocVA Launches Cutting-Edge Virtual Medical Assistant Services, Revolutionizing Healthcare Operations

Editor